PRI-101 / Priavoid - LARVOL DELTA

Priavoid…announced it will present…preclinical proof-of-concept data for its candidate PRI-101 in alpha-synucleinopathy models like Parkinson’s disease (PD) at the upcoming AD/PD 2026 International Conference (GlobeNewswire) - "The preclinical proof-of-concept data for PRI-101, a candidate designed to target alpha-synuclein (α-syn) aggregates, will be shared as a poster presentation and include encouraging efficacy data in several in vitro and in vivo PD models."

Preclinical • Parkinson's Disease